You just read:

Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study

News provided by

Oncopeptides AB

26 Mar, 2020, 09:22 GMT